Empire Biotechnologies
San Francisco
About Empire Biotechnologies
Empire Biotechnologies is developing an orally delivered, protein therapeutic called Mfge8 to treat diseases of malabsorption. It aims to develop and promote technologies that will bring positive change to the world. Empire Biotechnologies was formed in 2013 to execute its goal of commercializing platform technologies currently under development at the SUNY College of Nanoscale Science and Engineering and the University of California San Francisco.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $340.0K
- Funding stage: Seed
- Last round: Non-Equity Assistance (Mar 2019)
- Website: empirebiotechnologies.com
- Phone: (612) 710-1954
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/empire-biotechnologies-140390 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.